Table 2 Active clinical trials in tumors with CXCR1 and CXCR2 inhibitors

CXCR2

AZD5069 in combination with the androgen receptor antagonist, Enzalutamide

Metastatic Castration Resistant Prostate Cancer

NCT03177187

2

CXCR1/2

SX-682 in combination with the anti-PD-1, Nivolumab

RAS Mutated Microsatellite Stable Metastatic Colorectal Cancer

NCT04599140

2

CXCR1/2

SX-682 in combination with the anti-PD-1, Nivolumab

Metastatic Pancreatic Ductal Adenocarcinoma

NCT04477343

1

CXCR1/2

SX-682 in combination with the bifunctional fusion protein targeting TGF-β and PD-L1 (BinTrafusp Alfa or M7824) and with the cancer vaccine CV301 TRICOM targeting carcinoembryonic antigen (CEA) and mucin1 protein (MUC1)

Advanced Solid Tumors (STAT)

NCT04574583

2

CXCR1/2

SX-682 in combination with the anti-PD-1, Pembrolizumab

Metastatic Melanoma

NCT03161431

1

CXCR1/2

Navarixin in combination with the anti-PD-1, Pembrolizumab

Advanced/Metastatic Solid Tumors (Non-small Cell Lung Cancer, Castration Resistant Prostate Cancer, Microsatellite Stable Colorectal Cancer)

NCT03473925

2